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Abstract: The current cardiovascular risk tables are based on a 10-year
period and therefore, do not allow for predictions in the short or medium
term. Thus, we are unable to take more aggressive therapeutic decisions
when this risk is very high.
To develop and validate a predictive model of cardiovascular
disease (CVD), to enable calculation of risk in the short, medium
and long term in the general population.
Cohort study with 14 years of follow-up (1992–2006) was obtained
through random sampling of 342,667 inhabitants in a Spanish region.
Main outcome: time-to-CVD. The sample was randomly divided
into 2 parts [823 (80%), construction; 227 (20%), validation]. A
stepwise Cox model was constructed to determine which variables at
baseline (age, sex, blood pressure, etc) were associated with CVD. The
model was adapted to a points system and risk groups based on
epidemiological criteria (sensitivity and specificity) were established.
The risk associated with each score was calculated every 2 years up to a
maximum of 14. The estimated model was validated by calculating the
C-statistic and comparison between observed and expected events.
In the construction sample, 76 patients experienced a CVD during
the follow-up (82 cases per 10,000 person-years). Factors in the modelhD, Isabel Vigo-Ag
il-Guille´n, MD, PhD
and the comparison between expected and observed events was not
significant (P: 0.49–0.75).
We constructed and validated a scoring system able to determine,
with a very high discriminating power, which patients will develop a
CVD in the short, medium, and long term (maximum 14 years).
Validation studies are needed for the model constructed.
(Medicine 94(47):e1980)
Abbreviations: ABI = ankle brachial index, AUC = area under the
receiver operating characteristic curve, BMI = body mass index, CI
= confidence interval, CVD = cardiovascular diseases, DBP =
diastolic blood pressure, FBG = fasting blood glucose, HDL-c =
high-density lipoprotein cholesterol, NLR = negative likelihood
ratio, PLR = positive likelihood ratio, SBP = systolic blood
pressure, SCORE = Systematic Coronary Risk Evaluation, TC =
total cholesterol.
INTRODUCTION
C ardiovascular diseases (CVD) with underlying atheroscle-rosis are the leading cause of mortality in the world.1 As a
result, predictive models of CVD have been obtained to deter-
mine which patients are more likely to develop a disease of this
nature and in turn to take action on modifiable factors to
decrease the likelihood of CVD.2 Because these models come
from complex mathematical expressions, they, however, have
been transformed into points systems so that health pro-
fessionals can calculate the probability of CVD by performing
simple sums to determine the benefits of a possible intervention
on cardiovascular risk factors.3
As a reference, the Systematic COronary Risk Evaluation
risk chart (SCORE) is used in Europe whereas the United States
uses the Framingham risk table.2 These risk charts are based on
a follow-up of 10 years and thus do not allow for accurate
predictions in periods shorter (short or medium term) or longer
than 10 years (long term). This is a clinically important ques-
tion, because if we know that a patient has a high probability of
developing CVD in the short term (eg, 2 years), we should give
more intense drug and nonpharmacological therapy, because
failing to do so may result in the patient experiencing a CVD.
Given that we are unable to obtain short- to medium-term
probabilities from the current points systems, we conducted a
study in a Spanish region in which we constructed and validated
a predictive model for CVD of the proposed features using a
population-based cohort followed up for a period of 14 years.provide a tool to help us make treatment





The study population comprised inhabitants of the pro-
vince of Albacete (Spain) who were at least 18 years of age
(adults). In 1991, this province consisted of 342,667 inhabitants,
equivalent to 0.89% of the whole country.4
Study Design and Participants
This was a population-based cohort study with a maximum
follow-up of 14 years. The cohort was recruited through a 3-
stage sampling design of all the inhabitants in the province of
Albacete registered in the 1991 census. The first phase consisted
of a stratified sample based on groups according to the size of
the population of the nucleus of residence (capital, 39.7%;
>10,000, 23.3%; 2001–10,000, 20.8%; 501–2000, 14.5%;
and <501, 1.7%); the second phase was based on a cluster
sampling of the municipalities contained in the above groups,
and the final phase was a simple random sampling. The sample
size in each municipality was proportional to the size of its
population. This process (baseline) was conducted between
February 1, 1992 and September 5, 1994. Between July 13,
2002 and December 2, 2006, a second visit to the study
participants (follow-up) was performed. For both processes,
the selected patients were contacted by mail (up to 2 times) and
by telephoning those who did not respond. Patients in secondary
cardiovascular prevention were excluded from this study.
Variables and Measurements
The primary study variable was the time to the first
occurrence of CVD (time-to-event data). This (date of event
occurrence) was obtained from the patient’s clinical documents
and was defined as presenting at least one of the following
conditions: angina of any kind, myocardial infarction, stroke,
peripheral arterial disease of the lower limbs, or death from
CVD. Mortality (date and cause) was obtained through the
patient’s death certificate. Secondary variables were sex;
personal history of hypertension, diabetes, and dyslipidemia;
family history of coronary heart disease, left ventricular hyper-
trophy; occupational physical activity (heavy or moderate
activity; light activity); age (years); body mass index (BMI)
(kg/m2); systolic (SBP) and diastolic blood pressure (mm Hg);
cigarettes per day; fasting blood glucose (mmol/L); total cho-
lesterol (TC) (mmol/L); high-density lipoprotein cholesterol
(mmol/L); triglycerides (mmol/L); fibrinogen (mmol/L); heart
rate (bpm); and ankle brachial index (ABI). Moreover, the
product of the SBP and heart rate was used.5
A patient was considered to have a personal history of
hypertension, dyslipidemia, or diabetes when there was daily
drug treatment or the patient responded affirmatively to the
question: Have you been told by your doctor that you have
diabetes, hypertension, or hypercholesterolemia? Sex, date of
birth, number of cigarettes smoked (as in other studies,2 this
variable had a value of 0 when the patient was either a non-
smoker or a former smoker), and occupational physical activity
were obtained through interviews with the patient. The latter
was measured according to the Food and Agriculture Organiz-
ation of the United Nations and the World Health Organization:
light activity: activity associated with sitting at a desk or behind
a counter with automated instruments; moderate activity: con-
Artigao-Ro´denas et altinuous light physical activity, such as light work in industry or
in agriculture out of season; intense activity: heavy work and at
times, energetic (agricultural production, mining, or steel
2 | www.md-journal.comwork). If a person was not working, they were classified as
performing light activity.6 In addition, when a relative (parents,
children, and/or siblings) had suffered an event before 56 years
of age this was considered to be a family history of ischemic
heart disease. This variable was collected by interview with
the patient.
Left ventricular hypertrophy and heart rate were deter-
mined through an electrocardiogram. The variables relating to
blood tests were obtained after a minimum 12-hour fast. The
BMI was calculated by measuring the weight and height of the
patient with calibrated equipment and with the patients in
underwear and barefoot. Blood pressure was measured using
a sphygmomanometer and stethoscope following the pro-
cedures regulated by the guidelines recommended in the con-
sensus to control hypertension in Spain published in 1990 by the
Ministry of Health and Consumer Affairs.7 Finally, the ABI was
measured through Doppler ultrasound equipment and a sphyg-
momanometer.8
Sample Size
The original recruitment of patients was intended to esti-
mate the prevalence of peripheral arterial disease.8 With this
sample size, we determined how many patients had to be
recruited in each stratum (see Study design and participants).
The study estimating that prevalence finished and the patients
were followed in a new study to determine prognostic factors for
CVD. Because the original sample size was not calculated for
this purpose, the accuracy of the sample was estimated with the
new objectives (to construct and validate a new diagnostic test):
construction: A total of 823 people, of whom 76 had a CVD
(9.23%), were included. Expecting to find a specificity of 75%
and establishing a confidence level of 95%, the accuracy in
estimating the specificity was 3.11%. Validation: in this sample,
26 of the 227 had a CVD. Assuming an area under the receiver
operating characteristic curve (AUC) of 0.90 and establishing a
confidence level of 95% to contrast an AUC different from 0.5, a
power of contrast close to 100% was obtained.9
Statistical Methods
General: absolute and relative frequencies were used to
describe the qualitative variables, whereas for quantitative
variables means and standard deviations were used. All analyses
were performed with a¼ 5% and for each relevant parameter,
its associated confidence interval (CI) was calculated. All
analyses were performed using IBM SPSS Statistics 19
(IBM, Armonk, NY), Epidat 3.1 (Junta de Galicia, Galicia,
Spain), Microsoft Office Excel 2007 (Microsoft, Redmond,
Washington DC), and R 2.13.2.
Comparison of patients who completed the study and lost
patients: a comparison between these 2 groups was performed
using x2 tests (Pearson or Fisher) and Student t test, according to
the type of each variable. Comparison of patients in the con-
struction and validation samples: the patients who participated
in the study (no losses) were randomly divided into 2 groups: the
construction sample (80% of the sample) and the validation
sample (20%). To verify that there were no differences between
the 2 groups, the same tests as performed on the comparison of
the losses were used.
Construction of the model: in the construction sample
(80%), a multivariate Cox regression model was performed
Medicine  Volume 94, Number 47, November 2015to identify which variables were associated with CVD. For this,
a forward stepwise algorithm based on the likelihood ratio test
to determine those variables that may better predict CVD was
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.






the Study n¼ 192
n(%)/x s P
Sex
Male 459 (49.7) 94 (49.0) 0.179
Female 591 (56.3) 98 (51.0)
Hypertension
Yes 191 (18.0) 24 (12.5) 0.055
No 859 (81.8) 168 (87.5)
Diabetes
Yes 78 (7.4) 10 (5.2) 0.270
No 972 (92.6) 182 (94.8)
Dyslipidemia
Yes 146 (13.9) 15 (7.8) 0.021
No 904 (86.1) 177 (92.2)
Family History of Coronary Heart Disease
Yes 108 (10.3) 19 (9.9) 0.870
No 942 (89.7) 173 (90.1)
Left Ventricular Hypertrophy
Yes 27 (2.6) 3 (1.6) 0.402
No 1023 (97.4) 189 (98.4)
Occupational Physical Activity
Heavy or moderate 611 (58.2) 121 (63.0) 0.211
Light 439 (41.8) 71 (37.0)
Age (years) 47.4 17.4 43.3 18.2 0.003
BMI (kg/m2) 27.5 4.9 26.7 4.5 0.046
SBP (mm Hg) 132.6 21.3 127.1 22.8 0.001
DBP (mm Hg) 81.6 12.3 78.8 13.3 0.004
Cigarettes per day 5.6 10.4 5.5 9.0 0.919
FBG (mmol/L) 5.6 1.7 5.4 1.0 0.186
TC (mmol/L) 5.2 1.0 5.0 1.0 0.034
HDL-c (mmol/L) 1.2 0.3 1.2 0.3 0.392
Triglycerides (mmol/L) 1.2 0.8 1.1 0.7 0.081
Fibrinogen (mmol/L) 0.099 0.021 0.096 0.019 0.071
Heart rate (bpm) 73.5 12.6 72.6 12.5 0.363
ABI 1.06 0.13 1.08 0.12 0.026
ABI¼ ankle brachial index, BMI¼ body mass index, DBP¼ diastolic blood pressure, FBG¼ fasting blood glucose, HDL-c¼ high-density
lipoprotein cholesterol, n (%)¼ absolute frequency (relative frequency), SBP¼ systolic blood pressure, TC¼ total cholesterol, x s¼mean
Medicine  Volume 94, Number 47, November 2015 The Puras-GEVA Chartused. The goodness-of-fit of the model was assessed with the
likelihood ratio test and verification of the proportional risks
was evaluated using the Schoenfeld residuals method. After
estimating the model parameters (b coefficients), through the
methodology of the Framingham study,10 a points system was
constructed taking into account the specific weight of each
variable in the development of CVD (b coefficients). In other
words, the b coefficients were adapted to a system that can be
used by health professionals systematically and without requir-
ing the use of electronic devices to perform the calculations,
because categorizations of cardiovascular risk factors are made
to which a score is associated, according to the b coefficient of
said factor obtained in the multivariate model.10 The points and
their associated risk were calculated every 2 years up to a
maximum of 14 years. The following cutoff points were chosen:
standard deviation.optimal point: the score that minimized the square root of (1-
sensitivity)2þ (1-specificity)2; confirmation point: the mini-
mum score value that had a positive likelihood ratio greater
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.than or equal to 10; discard point: the maximum score that had a
negative likelihood ratio of less than 0.1. Points 2 and 3 were
chosen because, according to the School of Evidence Based
Medicine, they are those that permit conclusive confirmation or
discarding of positivity and negativity, respectively, of a diag-
nostic test. Furthermore, CVD risk groups were formed using
the points obtained previously: low risk (below Discard point),
medium risk (from the discard point to the optimal point), high
risk (from the optimal point to the confirmation point), and very
high risk (greater than or equal to the confirmation point). This
methodology has been used in similar studies.11,12
Validation: the points system was implemented in the
validation sample (20%) and the AUC and the C-statistic were
calculated. In addition, the survival of the risk groups was
compared using the log-rank test and the survival curves were
plotted using the Kaplan–Meier technique. Finally, the
observed and expected events were plotted and compared every
2 years (up to a maximum of 14 years) using the x2 test.
www.md-journal.com | 3
TABLE 2. Descriptive Analysis for Construction and Validation Samples in Albacete (Spain), 1992 to 1994 Data
Variable
Construction Sample
n¼ 823 n(%)/x s
Validation Sample
n¼ 227 n(%)/x s P
Cardiovascular Disease
Yes 76 (9.2) 26 (11.5) 0.318
No 747 (90.8) 201 (88.5)
Sex
Male 355 (43.1) 104 (45.8) 0.471
Female 468 (56.9) 123 (54.2)
Hypertension
Yes 156 (19.0) 35 (15.4) 0.221
No 667 (81.0) 192 (84.6)
Diabetes
Yes 63 (7.7) 15 (6.6) 0.594
No 760 (92.3) 212 (93.4)
Dyslipidemia
Yes 118 (14.3) 28 (12.3) 0.440
No 705 (85.7) 199 (87.7)
Family History of Coronary Heart Disease
Yes 91(11.1) 17 (7.5) 0.117
No 732(88.9) 210 (92.5)
Left Ventricular Hypertrophy
Yes 24 (2.9) 3 (1.3) 0.179
No 799 (97.1) 224 (98.7)
Occupational Physical Activity
Heavy or moderate 480 (58.3) 131 (57.7) 0.868
Light 343 (41.7) 96 (42.3)
Age (years) 47.4 17.1 47.1 18.0 0.794
BMI (kg/m2) 27.6 5.0 27.3 4.8 0.490
SBP (mm Hg) 133.3 21.5 130.3 20.7 0.061
DBP (mm Hg) 81.7 12.5 81.1 11.7 0.473
Cigarettes per day 5.6 10.7 5.9 9.5 0.663
FBG (mmol/L) 5.6 1.7 5.5 1.7 0.666
TC (mmol/L) 5.2 1.0 5.2 1.0 0.346
HDL-c (mmol/L) 1.2 0.3 1.2 0.3 0.610
Triglycerides (mmol/L) 1.2 0.8 1.2 0.7 0.769
Fibrinogen (mmol/L) 0.099 0.021 0.099 0.020 0.699
Heart rate (bpm) 73.6 12.8 73.2 12.0 0.599
ABI 1.06 0.13 1.07 0.14 0.054
ABI¼ ankle brachial index, BMI¼ body mass index, DBP¼ diastolic blood pressure, FBG¼ fasting blood glucose, HDL-c¼ high density
y),
Artigao-Ro´denas et al Medicine  Volume 94, Number 47, November 2015Ethical Issues
The study was approved by the Ethics Committee of the
General University Hospital of Albacete and carried out in
accordance with the ethical standards set forth in the Declaration
of Helsinki of 1964 and its subsequent amendments. All patients
gave written informed consent before inclusion in the study.
RESULTS
Of 1322 patients, 80 were excluded for having a history of
CVD, leaving a total of 1242 individuals who were followed until
the development of a cardiovascular event. During the study
period, no information was obtained from 192 patients, thus they
were excluded. Table 1 shows the characteristics of those who
lipoprotein cholesterol, n (%)¼ absolute frequency (relative frequenc
standard deviation.remained in the study and those who dropped out, highlighting
some significant differences between the 2 samples (dyslipide-
mia, age, BMI, SBP, diastolic blood pressure , TC, and ABI).
4 | www.md-journal.comOnce the sample was divided into 2 groups (80% and
20%); no statistically significant differences were seen (P-
values between 0.054 and 0.868). In these samples, the majority
was women, there were patients with cardiovascular risk fac-
tors, a majority of the patients carried out moderate or intense
activity at work, and the average age was approximately 47
years (see Table 2).
The construction sample consisted of 823 individuals, of
whom 76 had a CVD during the follow-up (33 fatal), equivalent
to an incidence density of 82 cases per 10,000 person-years
(95% CI: 65–103; 36 fatal, 95% CI: 25–50). Regarding the
multivariate model (Table 3), the following profile of prog-
nostic factors for CVD was obtained: male sex, diabetes, left
ventricular hypertrophy, light occupational physical activity,
SBP¼ systolic blood pressure, TC¼ total cholesterol, x s¼meanolder age, higher value of SBP heart rate, higher number of
cigarettes per day, and higher values of TC. The overall model
was highly significant (P< 0.001), that is, our model explained
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
value were obtained (Fig. 2). When comparing survival between
the different risk groups (Fig. 3), we observed that as the risk
category increased, the probability of experiencing a CVD
TABLE 3. Multivariable-Adjusted Cox Proportional Hazards Regression Coefficients for 14-Year Risk of Cardiovascular Disease in
Albacete (Spain), 1992 to 1994 Data
Variable b Coefficient SE Adjusted HR 95% CI (Adjusted HR) P
Male sex 0.717 0.277 2.047 1.190–3.522 0.010
Diabetes 0.600 0.296 1.823 1.021–3.254 0.042
LVH 0.948 0.365 2.580 1.262–5.276 0.009
Heavy or moderate occupational PA 0.312 0.253 0.732 0.446–1.201 0.216
Age (years) 0.089 0.012 1.094 1.069–1.119 <0.001
SBP heart rate (per 1000 mm Hg bpm) 0.055 0.045 1.057 0.968–1.154 0.220
Cigarettes per day 0.016 0.013 1.016 0.991–1.042 0.214
TC (mmol/L) 0.248 0.127 1.281 0.999–1.643 0.050
No TC measurement was available for 27 patients (3.28%). There were no missing data for the rest of the variables. The final model was therefore
constructed with 796 patients.
Goodness-of-fit of the model: x2¼ 144.1, P< 0.001.
hyp
Medicine  Volume 94, Number 47, November 2015 The Puras-GEVA Chartthe development of CVD better than the null model (model with
no explanatory variables), and provided the following cutoff
points: optimal, 10 (square root¼ 0.343); discard, 7 (negative
likelihood ratio¼ 0.07); and confirmation, 14 (positive like-
lihood ratio¼ 10.56). The probabilities of each of the possible
scores, along with its associated risk every 2 years (up to a
CI¼ confidence interval, HR¼ hazard ratio, LVH¼ left ventricular
standard error, TC¼ total cholesterol.maximum of 14 years) are reflected in Table 4. The scoring
system constructed through the multivariate model is shown in
Figure 1.
TABLE 4. Likelihood (%) of Having a Cardiovascular Disease
by Score and Follow-Up Time in Albacete (Spain), 1992 to
1994 Data
Score/
Years 2 4 6 8 10 12 14
1 0.01 0.02 0.03 0.04 0.06 0.09 0.11
0 0.01 0.03 0.04 0.07 0.09 0.15 0.17
1 0.02 0.04 0.07 0.11 0.15 0.23 0.27
2 0.03 0.07 0.10 0.17 0.23 0.36 0.42
3 0.05 0.11 0.16 0.27 0.36 0.57 0.66
4 0.07 0.17 0.25 0.42 0.56 0.88 1.03
5 0.11 0.26 0.39 0.65 0.88 1.38 1.61
6 0.18 0.41 0.62 1.02 1.38 2.15 2.51
7 0.28 0.64 0.96 1.59 2.14 3.34 3.89
8 0.43 0.99 1.50 2.47 3.33 5.18 6.02
9 0.67 1.55 2.34 3.84 5.16 7.98 9.25
10 1.05 2.41 3.63 5.94 7.95 12.19 14.08
11 1.64 3.75 5.62 9.13 12.15 18.40 21.13
12 2.55 5.80 8.65 13.91 18.34 27.23 31.01
13 3.96 8.92 13.20 20.89 27.16 39.18 44.04
14 6.13 13.60 19.86 30.68 39.07 54.05 59.67
15 9.42 20.43 29.26 43.62 53.93 70.36 75.83
16 14.33 30.05 41.81 59.19 70.24 85.07 89.15
17 21.49 42.82 57.12 75.38 84.97 94.89 96.90
18 31.50 58.28 73.40 88.83 94.84 99.05 99.56
19 44.66 74.52 87.39 96.75 99.03 99.93 99.98
20 60.36 88.21 96.08 99.53 99.93 100.00 100.00
21 76.48 96.47 99.37 99.98 100.00 100.00 100.00
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.As regards the validation sample, a C-statistic value of
0.886 (standard error¼ 0.061) and an AUC with a very similar
ertrophy, PA¼ physical activity, SBP¼ systolic blood pressure, SE¼FIGURE 1. Predictive model to determine which patients will
suffer a cardiovascular disease within a maximum period of 14
years. Definition of occupational physical activity: light activity:
activity associated with sitting at a desk or behind a counter with
automated instruments; moderate activity: continuous light
physical activity, such as light work in industry or in agriculture
out of season; intense activity: heavy work and, at times, energetic
(agricultural production, mining, or steel work). If a person was
not working, he or she was classified as performing light activity.
LVH¼ left ventricular hypertrophy, PA¼physical activity, SBP¼
systolic blood pressure
www.md-journal.com | 5
FIGURE 2. Areaunder the receiver operatingcharacteristic curveof
the points system in the validation sample. AUC¼ area under the
Artigao-Ro´denas et alincreased very significantly (P< 0.001). Finally, comparison
between the expected and observed events in all risk groups
every 2 years (Fig. 4) showed no statistically significant differ-
ences (P-values between 0.49 and 0.75).
DISCUSSION
Summary
This study constructed and validated a cardiovascular risk
table with primary data to determine the risk every 2 years, up to
receiver operating characteristic curve, CI¼ confidence interval.a maximum of 14 years. The results enable us to make decisions
in the short, medium, and long term to prevent CVD in a
new patient.
FIGURE 3. Differences between the different risk groups con-
structed in the validation sample.
6 | www.md-journal.comStrengths and Limitations of the Study
The main strength of this study is the methodology fol-
lowed in constructing this cardiovascular risk scale because,
unlike other risk tables,2 it enables us to make decisions in the
short and medium term. Thus, if a new patient has a high
probability of developing CVD in the short term, we should
carry out more intensive treatment of the factors in our points
system on which it is possible to act (TC, SBP, and smoking).
Moreover, we have included new factors that do not appear in
the cardiovascular risk tables used.2 Finally, regarding statisti-
cal issues, a very high discriminatory power was obtained.
To minimize possible selection bias, we used a random
sample design that considered the whole population in the
province we were analyzing. Information bias was minimized
because calibrated and validated equipment was used, and great
care was taken when measuring all parameters. In addition, all
the medical records and hospital reports of each participant
were comprehensively reviewed. Finally, although we collected
our data in the early 1990s (baseline) and early 2000s (second
visit), we must also consider that the data collection for both the
Framingham Heart Study and the SCORE project was per-
formed before our study and these tables are still being used
today in daily clinical practice around the world.2
Regarding statistical issues, the sample size used was
smaller than in other risk scales.2 We, however, must bear in
mind that this size was sufficient for the proposed objectives
(validation power close to 100%), which, added to a sample
design of the defined characteristics, provided great validity to
our findings. The constructed model obtained factors that were
nonsignificant independently (each factor separately). When
constructing the model, the choice of variables, however, was
performed using a forward stepwise algorithm based on the
likelihood ratio test; thus, when these factors were entered into
the model they did reach statistical significance (P< 0.05). We
must also highlight that we are considering the totality of the
constructed model,13 that is, its discriminatory capacity and the
obtaining of results similar to reality (observed–expected com-
parison), which as a whole was very satisfactory (C-statistic and
AUC close to 90%, and no differences found between observed
and expected events).
Comparison With the Existing Literature
Our methodology has differences when compared with the
models mainly used in Europe and United States (SCORE and
Framingham). First, we must take into account that these
models only allow for long-term predictions, whereas ours
enables decision making in the short, medium, and long term.
The type of sampling used in this study was completely random,
whereas the Framingham study participants were volunteers
and in SCORE, there were some patients from working popu-
lation cohorts. Finally, the age range of the Framingham and
SCORE studies is more restricted, whereas our study allows the
constructed scale to be applied to all adults (18 years). The
Framingham and SCORE studies, however, have a minimum
and maximum patient age for their use.2
The factors found in our model are consistent with the
current literature2 except that the product of the heart rate and
SBP is used in a novel way in our model. As this variable has
shown its weight in predicting CVD,5 its weight is logical and
expected when determining which patients will develop CVD.
Medicine  Volume 94, Number 47, November 2015Secondly, work activity other than sitting at a desk or behind a
counter with automated instruments had a protective nature in
our outcome. Given that other studies have found that exercise
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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poor (because otherwise the patient could not perform their
work properly), it makes sense to find this factor in our risk scale
as well.14 Finally, quantifying smoking with the number of
cigarettes enables setting targets in patients who are smokers so
that a partial reduction of the habit could lead to a decrease in
cardiovascular risk. As this factor has only been assessed in a
binary form in the SCORE and Framingham studies, a partial
reduction in the number of cigarettes in the patient who smokes
does not produce a decreased risk.2
Assessing the discriminating power of the model in deter-
mining which patients will suffer a CVD gave an AUC of 0.90
and a C-statistic very similar to this value. The other scales
obtained a maximum value of 0.82 in their internal validation.2
Hence, if we apply our model in other geographical areas and
obtain a value similar to that found in our validation sample, our
risk scale could become an alternative to the scales of previous
studies. Nonetheless, because heart rate and work activity must
be included, these variables should be taken into account in the
validation of our predictive model on data from cohort studies
conducted in other geographical areas.
Implications for Research and Practice
The preparation and internal validation of this new cardi-
ovascular risk scale with a higher number of discriminating
power than those currently known indicates that, if similar
results are obtained in other populations, our predictive model
could become a reference when calculating the cardiovascular
risk in the general population. We must be cautious though, we
only applied this scale in the province of Albacete. The authors
propose the validation of this predictive model in other popu-
lations. If this validation achieves results similar to ours, we can
make decisions in the short, medium, and long term, agreeing
upon realistic targets with smokers (partial reduction), control-
ling heart rate, and keeping in mind the work activity of the
participant, in addition to other known and treated risk factors in
preventing CVD.
CONCLUSIONS
This study developed and validated a points system able to
determine, with a very high discriminating power, which
FIGURE 4. Comparison between observed and expected events ipatients will develop a CVD within a maximum period of 14
years. This discriminating power was higher than in the known
scales. Therefore, if these results are maintained in validation
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.studies in other geographical areas, the cardiovascular risk scale
prepared in this study may be proposed as a tool for use in
clinical practice to reduce the incidence of CVD in the
general population.
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